Skip to main content
S&P 5007,759.04-0.55%DOW51,108.06-0.14%NASDAQ27,222.18-1.15%BTC$80,801.00-3.22%ETH$2,421.12-5.78%GOLD$4,155.00+0.35%OIL$90.84+2.90%
Smart Investors Daily
SID Premium
PP

NASDAQ · PPCB

Propanc Biopharma, Inc. Common Stock

Healthcare · Biotechnology

$0.50

Down-$0.03 (-5.78%)

Updated Oct 8, 2026, 5:19 PM

SID Score

4.6/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
9.77M
P/E ratio
-0.15
Dividend yield
0.00%
52-week range
$0.09 – $6.79
Volume
877.97K
Avg. volume
330.85K

Price performance · PPCB

PPCB price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 7, 2026

PPCB closed at $0.50 after 21 trading sessions, down 49.63% for the selected period.

Last close
$0.50
Period change
-49.63%
Period low
$0.49
Period high
$0.99
Daily close
View OHLC price history
PPCB OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 7, 2026$0.499$0.5071$0.46$0.4987877.97K
Oct 6, 2026$0.483$0.53$0.483$0.4913191.39K
Oct 5, 2026$0.51$0.5266$0.4899$0.5092.29K
Oct 2, 2026$0.5059$0.53$0.50$0.507572.27K
Oct 1, 2026$0.49$0.5178$0.49$0.50183K
Sep 30, 2026$0.516$0.5215$0.4714$0.494135.38K
Sep 29, 2026$0.515$0.5515$0.50$0.5123145.25K
Sep 28, 2026$0.615$0.6228$0.5178$0.5334421.65K
Sep 25, 2026$0.5911$0.6698$0.591$0.6303384.92K
Sep 24, 2026$0.63$0.6667$0.56$0.6018192.88K
Sep 23, 2026$0.6393$0.6525$0.6004$0.628194.13K
Sep 22, 2026$0.6469$0.6845$0.6376$0.651424.57K
Sep 21, 2026$0.6102$0.6484$0.595$0.6297144.75K
Sep 18, 2026$0.663$0.6655$0.6029$0.61160.54K
Sep 17, 2026$0.641$0.7321$0.629$0.63449.8K
Sep 16, 2026$0.848$0.8599$0.6253$0.6351.1M
Sep 15, 2026$0.86$0.8803$0.813$0.82174.11K
Sep 14, 2026$0.90$0.9106$0.8283$0.85282.88K
Sep 11, 2026$0.9222$0.9349$0.8744$0.921233.02K
Sep 10, 2026$0.9734$0.9762$0.936$0.9428129K
Sep 9, 2026$1.01$1.03$0.915$0.99304.91K

Latest PPCB news

The latest Smart Investors Daily articles mentioning PPCB.

Stock researchCompany · Overview

PPCB research

Overview

Company profile and research snapshot.

Company profile

Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 29, 2026

Propanc Biopharma Provides Corporate Update & Year-End June 30, 2025-26, Financial Results

Plans To Commence World-First Phase 1b First-In-Human (FIH) Study of PRP Q1, 2027MELBOURNE, Australia, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced an update on corporate progress and reported year-end financial results as of June 30, 2026 (Year end June 30). CORPORATE HIGHLIGHTS To commence

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By